Ramin Farboudmanesch, MD
Gastroenterology · Chevy Chase, MDNPI 1669433215
Payments from drug & device makers
Across 358 payments — averaging $99.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- QOL Medical, LLC$624
- Bristol Myers Squibb$482
- Regeneron Healthcare Solutions, Inc.$447
- Novo Nordisk$339
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,41996%
- Education$2604%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $30,176 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 76 | $1,134 |
| QOL Medical, LLC | 25 | $624 |
| Bristol Myers Squibb | 67 | $482 |
| Regeneron Healthcare Solutions, Inc. | 11 | $447 |
| Novo Nordisk | 13 | $339 |
| Ferring Pharmaceuticals Inc. | 18 | $313 |
| Apollo Endosurgery US Inc | 2 | $266 |
| Pfizer | 14 | $263 |
| Phathom Pharmaceuticals, Inc. | 7 | $261 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $163 |
| Johnson & Johnson | 7 | $161 |
| Sanofi | 6 | $117 |
| Nestle Healthcare Nutrition Inc. | 4 | $101 |
| E.r. Squibb & Sons, L.L.C. | 1 | $90 |
| Intercept Pharmaceuticals, Inc. | 4 | $76 |
| Madrigal Pharmaceuticals | 3 | $71 |
| Lilly USA, LLC | 2 | $54 |
| Braintree Laboratories, Inc. | 3 | $50 |
| Gilead | 3 | $43 |
| Aspire Bariatrics, Inc. | 1 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Evoke Pharma, Inc. | 2 | $34 |
| Exact Sciences | 1 | $29 |
| Ambu Inc. | 1 | $28 |
| Echosens North America, Inc. | 1 | $27 |
| Boston Scientific | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $19 |
| Capsovision, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OverStitch Endoscopic Suturing System$170
- ORBERA Intragastric Balloon System$170
- DUPIXENT$134
- Wegovy$123
- DUOBRII$119
- ARAZLO$119
- ALTRENO$119
- SILIQ$119
- VOQUEZNA$113
- Sucraid$101
How this compares
$35,555 in reported general payments places this provider in the 85th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 81 | $14,171 |
| LinzessLinaclotide | 12 | $8,124 |
| VoqueznaVonoprazan Fumarate | 12 | $7,632 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 101 | $5,439 |
| Omeprazole | 133 | $1,458 |
| Dicyclomine Hcl | 35 | $1,420 |
| Sucralfate | 17 | $618 |
| Baclofen | 11 | $448 |
| Pantoprazole Sodium | 29 | $265 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 21 | $210 |
| Hydrocortisone | 30 | $153 |
| Amitriptyline Hcl | 20 | $122 |
| Duloxetine Hcl | 12 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ferring Pharmaceuticals Inc.Clenpiq | $313 | $14,17181 claims |
| AbbVieLinzess | $30,176 | $8,12412 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $261 | $7,63212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Chevy Chase
- Louis KormanChevy Chase$1.9M
- Erica CohenChevy Chase$1.1M
- Zachary BormanChevy Chase$520K
- Mohammed AliChevy Chase$49K
- Robert HardiChevy Chase$48K
- Kenolisa OnwuemeBaltimore$4.5M
- Paul ThuluvathBaltimore$3.6M
- Apurva ModiRockville$3.3M
- Marcia CantoBaltimore$1.6M
- Michael EpsteinAnnapolis$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.